Holen Sie sich die Stockscreener-App
4.07
10.30%
0.38
Vorhandelsmarkt:
4.20
0.13
+3.19%
Schlusskurs vom Vortag:
$3.69
Offen:
$3.81
24-Stunden-Volumen:
45,399
Relative Volume:
0.72
Marktkapitalisierung:
$43.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.09M
KGV:
-2.2865
EPS:
-1.78
Netto-Cashflow:
$-17.24M
1W Leistung:
+16.62%
1M Leistung:
+29.41%
6M Leistung:
-7.71%
1J Leistung:
+0.74%
1-Tages-Spanne:
$3.80
$4.10
1-Wochen-Bereich:
$3.45
$4.10
52-Wochen-Spanne:
$2.79
$11.99
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Vergleichen Sie LTRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
4.07 | 43.89M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Yahoo Finance
Lantern Pharma Extends CSO’s Employment Agreement - TipRanks
Lantern Pharma (NASDAQ:LTRN) Stock Price Up 13.3% – What’s Next? - Defense World
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Yahoo Finance
AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan - Insider Monkey
Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial - Yahoo Finance
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer - Yahoo Finance
15 AI News Updates That Broke The Internet - Insider Monkey
LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan
Lantern Pharma Shares Rise After Fast-Track Designation for Cancer Treatment - Marketscreener.com
LP-184 gains FDA fast track for triple negative breast cancer - Investing.com
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Eagle-Tribune
Lantern Pharma's LP-184 Shows 6x Better GBM Treatment Efficacy in Latest Trial Data | LTRN Stock News - StockTitan
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Business Wire
10 Best AI Penny Stocks Under $10 in 2024 - CoinCodex
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call Transcript - MSN
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - BioSpace
Lantern Pharma stock hits 52-week low at $3.0 amid market challenges - Investing.com
Lantern Pharma's Lung Cancer Drug Shows 86% Benefit Rate, Expands to Japan Trial | LTRN Stock News - StockTitan
32BJ Health Fund Selects Lantern as Surgery Network Partner - GlobeNewswire Inc.
III: TechBio News Day 👾 - substack.com
LTRN: Pediatric Rare Cancer in Focus - Yahoo Finance
Earnings call: Lantern Pharma reports Q3 2024 financials and trial updates - Investing.com India
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Stra - GuruFocus.com
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance
Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates - BioSpace
Starlight Therapeutics Assembles Elite Brain Cancer Advisory Board, Backed by Top Oncologists | LTRN Stock News - StockTitan
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board - Yahoo Finance
Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back - D Magazine
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET - BioSpace
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - ForexTV.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 - Business Wire
Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire
LP-184 Earns FDA Fast Track Designation in Glioblastoma - Targeted Oncology
FDA grants Fast Track Designation to LP-184 for GBM treatment - Investing.com Canada
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA - BioSpace
FDA Grants Fast Track Designation to LP-184 for Glioblastoma - OncLive
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Prom - GuruFocus.com
After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals - Stocks Telegraph
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):